You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SLL

Showing 26 - 50 of 503
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NHL, Leukemia Trial in Australia (ETH-155008)

Recruiting
  • NHL
  • Leukemia
  • Adelaide, South Australia, Australia
  • +4 more
Jun 8, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Nanjin (Orelabrutinib, Obinutuzumab, Fludarabine)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Nanjin, Jiangsu, China
    Department of Haematology, the First Affiliated Hospital of Nanj
Apr 12, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • (no location specified)
Nov 22, 2023

Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

Completed
Has Results
  • Non-Hodgkin's Lymphoma, Relapsed
  • +8 more
  • PBCAR20A
  • +2 more
  • Duarte, California
  • +4 more
Jan 4, 2023

T-cell Lymphoma, CLL/SLL Trial in Birmingham (Tazemetostat, Acalabrutinib and Tazemetostat)

Not yet recruiting
  • T-cell Lymphoma
  • CLL/SLL
  • Birmingham, Alabama
    University of Alabama at Birmingham
Aug 11, 2023

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in Rochester (Acalabrutinib, Rituximab)

Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Rochester, New York
    University of Rochester
Feb 7, 2022

Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Ibrutinib 420 mg)

Not yet recruiting
  • Autoimmune Hemolytic Anemia
  • +3 more
  • Ibrutinib 420 mg
  • (no location specified)
Jan 12, 2023

CLL/SLL Trial in Worldwide (Epcoritamab, Venetoclax)

Not yet recruiting
  • CLL/SLL
  • Antwerpen, Belgium
  • +23 more
Mar 28, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed Trial in Tianjin (Zanubrutinib, Fludarabine,

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
  • Zanubrutinib, bendamustine, rituximab
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Mar 18, 2022

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial

Active, not recruiting
  • Contiguous Stage II Small Lymphocytic Lymphoma
  • +11 more
  • MOR00208
  • +2 more
  • Columbus, Ohio
    The Ohio State University Comprehensive Cancer Center
Feb 24, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial in Columbus (acalabrutinib,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Columbus, Ohio
    Research Site
Mar 11, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Acalabrutinib, Obinutuzumab)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Basking Ridge, New Jersey
  • +7 more
Nov 9, 2022

Chronic Lymphocytic Leukemia, CLL, Relapsed CLL Trial (Dose combination 1-1, dose combination 1-2, Dose combination 1-3)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Dose combination 1-1
  • +5 more
  • (no location specified)
Nov 1, 2021

CLL/SLL Trial in Australia, United States (APG2575)

Recruiting
  • CLL/SLL
  • Duarte, California
  • +8 more
Feb 28, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in Japan (Venetoclax, Ibrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Nagoya-shi, Aichi, Japan
  • +19 more
Jan 25, 2023

B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (AS-1763)

Not yet recruiting
  • B-cell Malignancy
  • +7 more
  • (no location specified)
Oct 26, 2022

Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemia) Trial run by the NHLBI (PCI 32765)

Active, not recruiting
Has Results
  • Leukemia
  • +3 more
  • PCI 32765
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 2, 2021

Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia) Trial run by the National Heart, Lung, and Blood Institute

Active, not recruiting
Has Results
  • Small Lymphocytic Lymphoma
  • CLL (Chronic Lymphocytic Leukemia)
  • Fludarabine Phosphate
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 13, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in United States (Venetoclax monotherapy, Venetoclax

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Venetoclax monotherapy
  • Venetoclax with anti CD20 monoclonal antibody
  • Basking Ridge, New Jersey
  • +9 more
Mar 15, 2022

CLL/SLL Trial in China (ICP-022)

Active, not recruiting
  • CLL/SLL
  • Hefei, Anhui, China
  • +24 more
Jul 5, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial (Nemtabrutinib, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia
  • (no location specified)
Nov 30, 2022

Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia

Active, not recruiting
  • Relapsed/Refractory B Cell Malignancies
  • +3 more
  • Columbus, Ohio
  • +17 more
Aug 18, 2022

Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Beijing (MS-553)

Recruiting
  • Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Beijing, Xicheng District, China
    Peking University People's Hospital
Jun 23, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL) Trial in Switzerland, United

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Tucson, Arizona
  • +23 more
Dec 14, 2021

CLL, SLL Trial in Boston (Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab)

Terminated
Has Results
  • CLL
  • SLL
  • Boston, Massachusetts
  • +1 more
Jan 30, 2023